Elite Pharmaceuticals, Inc.

Item 7.01. Regulation FD Disclosure. On August 10, 2026, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) issued a press release announcing that the Company will host a conference call to discuss its financial results for the first quarter of fiscal year 2027 ended June 30, 2026, on Thursday, November 14, 2026, at 11:30 AM EDT. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Conference Call Information Date: August 14, 2026 ──────────────────────────────────────────────────────────────────────────── Time: 11:30 AM EDT Dial-in 1-800-346-7359 numbers: (domestic) 1-973-528-0008 (international) Conference 98840 number: Questions: dianne@elitepharma.com General questions by 5:00 PM EDT on Wednesday, November 12, 2026 Financial questions by 7:00 PM EDT on Friday, November 13, 2026 The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.